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Abstract 
Background: Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death in 
the United States and accounts for more than 17.3 million deaths per year with hyperlipidemia as 
one of the leading risk factors.  The 2013 American Heart Association/American College of 
Cardiology (AHA/ACC) hyperlipidemia guideline recommends healthy lifestyle habits, risk 
estimation of the development of cardiovascular disease using a risk calculator, and intensity 
dosed statin therapy.  There has been controversy among providers resulting in confusion and 
inconsistent application of the guideline.  Purpose: The purpose of this project was to examine 
provider adherence to the AHA/ACC hyperlipidemia guideline in a primary care clinic.  The 
evaluation included appropriate intensity statin therapy according to the ASCVD risk score and 
evidence of provider discussion of healthy lifestyle habits.  Methods: A retrospective chart 
review was conducted in which 150 patients between the ages of 45 to 75 were randomly 
selected who had an active diagnosis of hyperlipidemia and were currently on statin therapy.  
Documentation was reviewed for discussion of healthy lifestyle habits, a calculated ASCVD risk 
score, and appropriate intensity statin therapy.  Data was reviewed in 2015 and 2016.  Results: 
In this sample, 40% of patients with hyperlipidemia were not receiving the recommended statin 
therapy based on their ASCVD risk score, which had been calculated by the provider on 23% of 
patients.  Of statistical significance (p = 0.001), men (63%) were on appropriate intensity statin 
therapy, more often than women (37%).  Discussion of lifestyle modifications took place in 50% 
of the visits.  Conclusion: Based on the results of this review, there is room for improvement 
among providers in the evaluation and treatment of hyperlipidemia patients recommended by the 
2013 guideline.    
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Assessing Provider Adherence to the 2013 ACC/AHA Hyperlipidemia Guideline  
Cardiovascular disease is the leading cause of death in the United States.  It accounts for 
17.3 million deaths per year with an anticipated increase in annual mortality to more than 23.6 
million by 2030 (Mozaffarian et al., 2015).  Kentucky is ranked eighth in cardiovascular disease 
death rates accounting for 30% of all deaths in 2009 (Kentucky Cabinet for Health and Family 
Services, 2015).  It is imperative that health providers focus on improving cardiac health in order 
to reduce the burden of cardiovascular disease.  One key intervention is helping patients manage 
their cholesterol, a known risk factor for cardiac disease.  The advents of new treatment 
guidelines have not yet been fully endorsed by healthcare providers.  The purpose of this project 
was to examine provider adherence to the elements of the American Heart Association/American 
College of Cardiology hyperlipidemia guideline in a primary care clinic. 
Background and Significance 
Hyperlipidemia is present in one in six American adults (CDC, 2015).  It refers to 
increased levels of lipids or fats in the blood and is one of the most significant risk factors for 
atherosclerotic cardiovascular disease (ASCVD).  A lipid panel includes measurements of total 
cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL) and triglycerides.  
Total cholesterol is a measure of the total amount of cholesterol in the blood and is calculated 
from a formula including HDL, LDL, and triglycerides (CDC, 2015).  LDL is considered “bad” 
cholesterol and high levels can lead to plaque buildup in arteries causing heart disease and 
stroke.  HDL, the “good” cholesterol, absorbs cholesterol and carries it to the liver where it is 
flushed from the body.  Triglycerides are fats in the blood the body uses for energy (CDC, 2015).  
The risk for heart disease is doubled in individuals with high total cholesterol, defined as 
greater than 240 mg/dl. Seventy-three million adults in the United States have high low-density 
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lipoprotein (LDL), defined as greater than 189 mg/dL.  Less than half of adults with high LDL 
are receiving treatment to lower their levels and less than one in three adults with high LDL have 
the condition under control.  Some risk factors for hyperlipidemia are cannot be controlled, such 
as age, gender, and heredity; however, modifiable risk factors can be controlled and include an 
unhealthy diet, being overweight or obese, smoking, and lack of exercise (CDC, 2015).   
The previous hyperlipidemia clinical practice guideline was known as Adult Treatment 
Panel III (ATP III).  In addition to obtaining a fasting lipid panel, it recommended identifying the 
presence of clinical ASCVD and/or the presence of major risk factors other than LDL that may 
modify LDL goals (National Heart, Lung, and Blood Institute, 2001).  If more than two risk 
factors were present without a diagnosis of coronary heart disease, a risk score would be 
obtained using the Framingham calculator sorting them into one of three levels: <10%, 10-20%, 
and >20%.  The patient would then be placed into a risk category.  Based upon their risk, there 
would be an LDL goal, an LDL level at which to start lifestyle changes, and an LDL level at 
which to consider starting medication.  This guideline also recommended medications in addition 
to statins, such as bile acid sequestrants, nicotinic acid, and fibric acids (National Heart, Lung, 
and Blood Institute, 2001).   
Evolving evidence over the past fifteen years led to the development of an updated 
guideline for lipid management, which was published in 2013 by the American College of 
Cardiology and American Heart Association.  The goal was to provide primary care providers 
with evidence-based recommendations easy to use in the clinical setting (Stone et al., 2014).   A 
ten-year risk score, calculated by the Pooled Cohort Equation, is based on data from multiple 
community-based populations and is applicable to African-Americans and non-Hispanic men 
and women ages 40 to 75 with no preexisting cardiovascular disease (Stone et al., 2014).  In 
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contrast to the Pooled Cohort Equation, the Framingham calculator used in ATP III did not 
consider ethnicity other than Caucasian, a diagnosis of diabetes, and was calculated for ages 30-
79.  
The calculated ASCVD risk score ultimately determines the level of statin intensity and 
is an estimate of a person’s ten-year risk for a cardiovascular event (Stone et al, 2014).  The 
information required to calculate the risk is age, gender, race, total cholesterol, HDL, systolic 
blood pressure, if treatment for high blood pressure is present, diabetes diagnosis, and smoking 
status.  Statin therapy is recommended in any risk score greater than or equal to 7.5% (Stone et 
al., 2014).  
Reduction of ASCVD risk identified in the 2013 guideline includes lifestyle 
modifications (i.e. healthy diet, regular exercise, avoidance of tobacco, and healthy weight) and 
statin therapy.  The lifestyle modifications have been emphasized more than that of the ATP III, 
but it is the statin therapy that underwent the greater change.  Four main statin benefit groups 
have been identified (see Appendix B) with statin therapy divided into low-intensity, moderate-
intensity, and high-intensity (see Table 1).  In addition, specific medications are recommended 
along with their respective dosing.   
Based on evidence from randomized controlled trials, the 2013 guideline recommends 
using a fixed dose of a statin to reduce the risk of ASCVD in adults 21 years and older (Stone et 
al., 2014).  Research demonstrates that using a fixed moderate to high dose statin when initiating 
therapy results in a higher decrease in LDL than starting with a lower dose and titrating up.  
Previous guidelines have recommended specific LDL and cholesterol targets; however, there is 
no evidence to support this.  Therefore, the ACC/AHA guideline does not include 
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recommendations for specific LDL or non-HDL targets in the prevention of cardiovascular 
disease (O’Riordan, 2013). 
ASCVD Prevention 
 ASCVD prevention is dependent upon lifestyle modification as well as statin therapy.  A 
study by Barnard (1991), though dated, demonstrated the effect lifestyle modification has on 
serum lipid levels.  The program included 4,587 adults who attended a three-week lifestyle 
modification program consisting of a high complex carbohydrate, high-fiber, low fat, and low-
cholesterol diet.  In addition, patients were encouraged to engage in daily physical activity, 
primarily walking.  The post study intervention revealed total cholesterol values were reduced by 
23%, LDL was reduced by 23%, and triglyceride levels were reduced by 33% (Barnard, 1991).  
Though this research is over twenty years old, the principles remain applicable today.   
A healthy lifestyle defined by the AHA includes a healthy diet, regular exercise, 
avoidance of tobacco products, and maintaining a healthy weight. The recommended diet is one 
high in vegetables, fruits, whole grains, low-fat dairy products, and lean meats, with limited 
saturated fat and less than 2400mg of sodium intake daily (Claas & Arnett, 2016; McKibben, Al 
Rifai, Mathews, & Michos, 2016).  Adults should engage in moderate to vigorous physical 
activity three to four times a week lasting approximately forty minutes and include muscle-
strengthening exercises at least twice a week.  Healthy weight is defined as a BMI between 18.5 
and 24 kg/m2 and a waist circumference <35 inches (McKibben et al., 2016). 
 The changes in statin therapy were redesigned in the new 2013 guideline.  They are 
considered the first-line pharmaceutical treatment for patients with hyperlipidemia, but have also 
proven beneficial in primary prevention of ASCVD.  Not only do they lower LDL by as much as 
55%, they also improve endothelial lining, help stabilize atherosclerotic plaques, reduce 
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inflammation and damage from oxidative stress, and prevent platelet aggregation reducing the 
risk of a thrombus (Cleveland Clinic, 2015).  Statin therapy reduces the five-year risk of death, 
myocardial infarction, and stroke.  There is no evidence supporting the use of non-statin lipid-
lowering medications, such as Zetia, niacin, fibrates, and omega-3 fatty acids, in the primary 
prevention of ASCVD and should only be used if there is a documented statin intolerance (Last, 
Ference, & Menzel, 2017).  
There has been some controversy among health providers about the 2013 guidelines in 
comparison to ATP III.  Most of the controversy relates to statin prescribing in primary 
prevention of ASCVD.  Some feel the new Pooled Cohort Equation overestimates risk and 
reaches the 7.5% threshold for consideration of statin therapy for age alone (Newsome, 2014).  
Outside of the concerns regarding the potential overprescribing of statins, there is also the 
difficulty in changing practice from titrating therapy to a fixed dose.  Providers have had 
difficulty not treating to an LDL goal as identified by a specific number (Newsome, 2014).    
The previous perceived incidence of liver injury has been minimized, as there is little 
evidence to support liver toxicity from statins.  Providers still tend to over-monitor liver enzymes 
due to their continued fear of statin intolerance.  The concern regarding statin induced myopathy, 
reported in 1-29% of patients, is not a reason to discontinue its use.  The Statin Intolerance Panel 
encourages continued use of some form of statin therapy except in the instance of a true allergy.  
For those that are unable to tolerate daily dosing, weekly or every-other-day dosing with 
rosuvastatin or atorvastatin may still provide significant reductions in LDL.  Research has 
demonstrated that the statin benefit of ASCVD risk reduction greatly outweighs potential adverse 
effects (Robinson, 2014). Although statin prescribing among providers has increased over the 
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years, ways to overcome these controversies and improve provider prescribing of statins need to 
be investigated.    
Purpose 
The purpose of this project was to evaluate statin prescribing among providers at the UK 
Family and Community Medicine Clinic according to the 2013 ACC/AHA Hyperlipidemia 
Guideline.  The primary aim was to examine prescribing patterns among the healthcare 
providers.  Other aims of this project included how often discussion of lifestyle modifications 
and documentation of a calculated ASCVD risk score was present.  By examining current 
provider practices, baseline data will be provided for future quality improvement initiatives.   
Methods 
Design 
 A descriptive study using a retrospective chart review of 150 patients was examined for 
the current management of ASCVD risk and statin medication prescribing practices of primary 
care providers (PCPs) at the UK Family and Community Medicine Clinic.  The clinic is 
comprised of 20 attending physicians, 21 resident physicians, and 8 nurse practitioners that 
together see approximately 3500 patients a month.  They see patients of all ages throughout the 
lifespan.  
Sample 
 The UK Center for Clinical and Translational Science provided a list of all patients seen 
at the clinic from January 1, 2016, to September 30, 2016 and who met inclusion criteria. 
Patients included in the review were between the age of 45 to 75, diagnosed with the ICD10 
codes for high cholesterol, hyperlipidemia, or dyslipidemia, and currently on a statin medication.  
Patients excluded from the chart review include those less than 45, over age 75, no active 
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diagnosis of hyperlipidemia, or not on statin therapy.  The age of 45-75 was determined as that 
that is the age range used in the Pooled Cohort Equation.  A total of 443 patients were identified 
and from that list 150 were randomly chosen for review.  The chart review was conducted from 
the Allscripts electronic health record (AEHR).  IRB approval was obtained through the 
University of Kentucky. 
Data Collection 
 The charts for 150 patients seen for hyperlipidemia in 2016 were reviewed.  If they were 
a patient of the clinic and had been diagnosed with hyperlipidemia either in 2015 or before, a 
visit for hyperlipidemia in 2015 was also reviewed.  See Appendix A for all information 
collected ranging from demographics and co-morbid conditions to current and past treatment for 
hyperlipidemia.  Information was collected for 2016 and where possible, 2015.  The principle 
investigator calculated and recorded an ASCVD risk score for 2016 and 2015. 
The chart review was performed using a UK issued computer on a secured server 
network.  A codebook was created and all information was stored in an Excel spreadsheet on the 
principle investigators password protected computer.  Patient consent was waived in accordance 
with IRB regulations since the nature of the data collection was a retrospective medical record 
review, where patient identifiers were not collected.  
Data Analysis 
 The data collected was entered into an Excel spreadsheet and exported to the IBM 
Statistical Package for the Social Sciences (SPSS) software for statistical analysis.  Descriptive 
statistics and frequency distributions summarized the sample.  Bivariate analysis tested for 
differences in adherence by demographic and clinical variables.  Chi-square tests of association 
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and fisher’s exact tests were used for categorical variables.  Mann-Whitney U tests were used for 
differences with ordinal demographics.  A p-value of 0.05 determined statistical significance.  
Results 
  A total of 150 patients were randomly selected for inclusion in the chart review.  Of the 
150 patients reviewed in 2016, 138 were reviewed in 2015.  The other twelve patients were 
either diagnosed with hyperlipidemia in 2016, or were not seen at the clinic prior to 2016.  There 
was equal gender distribution and the majority (73%) classified themselves as Caucasian.  The 
age of the sample ranged from 45-75 with over 70% being between 50 and 70.  Sixty-five 
percent of the sample reviewed had a BMI greater than 30kg/m2.  Only 19% of the total sample 
currently smoked in both 2015 and 2016.  See Tables 2 and 3 for all demographic information.  
Hypertension, Diabetes, and Obesity were the most common co-morbidities among patients (see 
Chart 1).   
 In terms of lifestyle variables, providers addressed diet and exercise approximately 50% 
of the time in 2016.  This was slightly higher than in 2015, where diet and exercise were 
addressed 45% of the time.  In 2015, 30% of the sample reported making a lifestyle change in 
either diet or exercise.  This percentage was higher in 2016, wherein 45% of the sample had 
made some type of lifestyle change.  Among the 19% of current smokers, smoking cessation was 
discussed approximately 70% of the time in 2016 and 60% of the time in 2015.   
Looking at current statin prescribing, atorvastatin was the most common statin used 
(65%), followed by simvastatin and pravastatin each prescribed 16% of the time.  Over 50% of 
patients reviewed had been on a statin medication more than five years.  Fifty-nine percent were 
on appropriate statin therapy in 2016 and 53% were on appropriate therapy in 2015.  In 10% of 
those not on the appropriate statin intensity, clinical documentation was present to justify the 
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dosage.  Of statistical significance (p = 0.001), males (63%) were on appropriate statin therapy 
more often than females.  A calculated ASCVD risk score was present in 23.3% of the charts in 
2016 and 20.3% of the charts in 2015.  The mean ASCVD risk score was around 15% in both 
2016 and 2015.   
Lab monitoring and other previously recognized therapies for management of 
hyperlipidemia were also reviewed.  Liver enzymes were checked prior to statin initiation in 
90% of patients and liver enzymes and lipid panels were monitored yearly in almost 80% of 
patients.  No patients reviewed had been prescribed a bile acid sequestrant, 0.7% had been 
prescribed a niacin, 1.3% prescribed Zetia, 3.3% prescribed a fibrate, and 8.7% taking Omega-3 
fatty acids.   
Discussion 
 The purpose of this study was to determine if primary care providers at the UK Family 
and Community Medicine Clinic were following the recommendations of the 2013 
hyperlipidemia guideline and prescribing appropriate intensity statin therapy.  Adherence to the 
hyperlipidemia guideline can help in prevention of cardiovascular disease and the management 
of it.  Further, looking at the cost to the healthcare system, it is prudent for all providers to 
address this important issue.  The direct and indirect cost of cardiovascular disease totals more 
than $320.1 billion, including health expenditures and lost productivity (Mozaffarian et al., 
2015). 
 This sample was well representative in terms of gender and age. What was not well 
represented was ethnicity as the majority of patients seen were Caucasian.  It is interesting to 
note that 63% of males had appropriate statin therapy whereas only 37% of females were 
prescribed the appropriate dosage.  Prior to the most recent literature, cardiovascular disease was 
PROVIDER ADHERENCE TO HYPERLIPIDEMIA GUIDELINE
	   	   	  
	  
11	  
not well treated in women and research was lacking related to the benefit of statin therapy for 
primary prevention in women (McKibben et al., 2015).  This may say something to the emphasis 
providers give toward women and warrants further investigation.  
There is a high incidence of hypertension, diabetes, and obesity in patients with 
dyslipidemia.  Of the sample, fifty-one patients (34%) had all three co-morbidities: hypertension, 
diabetes, and obesity.  According to recent statistics from the World Health Organization 
(WHO), one in three adults worldwide has hypertension and 10% of people have diabetes.  From 
2013 to 2014, 38% of U.S. adults over the age of 20 were considered obese while 71% were 
considered overweight or obese (CDC, 2016).  It is interesting to note that only 19% of the 
sample smoked, especially since rates of smoking in Fayette County are approximately 25% 
(Kentucky Department for Public Health, 2008).  One might wonder if there were instances of 
smoking status not being documented or if efforts at encouraging and facilitating smoking 
cessation have been successful. 
According to the results of this review, 40% of patients are not receiving the appropriate 
intensity statin therapy recommended by the guideline.  Of the patients not on the appropriate 
statin intensity, clinical documentation to support the current dose was only found in 10%.  One 
possibility is that the dosage from 2015 was continued because the lipid panel had improved 
from the previous year.  Had an ASCVD risk score been calculated per recommendation of the 
guideline, the provider may have prescribed a higher intensity statin.  It could also be that with 
the presence of so many other issues, providers were focused on all the other chronic conditions 
and the statin was not re-evaluated due to time constraint (Parker et al., 2008).   
In addition, a calculated ASCVD risk score was only documented approximately 20% of 
the time.  This could indicate an over or underestimation of patient risk by not using a risk 
PROVIDER ADHERENCE TO HYPERLIPIDEMIA GUIDELINE
	   	   	  
	  
12	  
calculator.  Research has demonstrated that the use of a risk calculator to accurately estimate a 
patient’s cardiovascular risk improves statin prescribing among providers (Sekaran, Sussman, 
Xu, & Hayward, 2013).  Sixty-six percent of patients with an ASCVD risk calculated and 
documented were on appropriate statin therapy.  The calculated ASCVD risk score decreased 
from 2015 to 2016 in 54% of patients.  Of the 60% of patients on appropriate statin intensity 
therapy, 48% had a decrease in their risk score from 2015 to 2016.  Several of the risk scores 
present were documented as part of the patient’s diabetes care plan and were listed as < 7.5% or 
> 7.5%.  Some providers may have estimated the risk based upon their own assessment rather 
than actually calculating the risk score. 
 Heart healthy lifestyle habits are the foundation of ASCVD prevention.  According to this 
review, providers are only discussing healthy lifestyle habits approximately half of the time.  The 
majority of the patients included in this study were not at a healthy weight as evidenced by a 
BMI above 30.  Lifestyle modification remains a critical component prior to beginning and while 
on statin therapy and should be continually assessed (Stone et al., 2014).  Unfortunately, 
changing lifestyle habits is a perplexing problem for all healthcare providers.  Although 
approximately 60% of obese Americans are able to lose 5-10% of their body weight, only around 
5% are able to maintain the weight loss long-term (Nicklas, Huskey, Davis, & Wee, 2012).  
Providers have a level of inertia when discussing this because there is difficulty with patient 
motivation and there are not distinct therapies to prescribe.   
Barriers to Implementation 
 Barriers to implementation among providers include lack of knowledge about the latest 
recommendations, disagreeing with the core content, complexity of the guideline, and lack of 
time (Martin et al., 2015; Parker et al., 2008).  A study by Parker et al. (2008), determined that 
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some providers felt they were so busy taking care of patients, they did not have much time for 
reading journals and keeping up with the latest evidence.  However, the clinic in which this 
project was conducted is a resident training clinic associated with an academic facility and 
therefore should be well versed on the most recent guidelines.  Others felt the recommendations 
were not easy to use because of the complexity of the guideline.  Finally, it may be that providers 
feel that in a fifteen to twenty minute appointment, they do not have time to discuss all necessary 
elements and address only the most critical issues (Parker et al., 2008).   
 The use of the ASCVD risk estimator has not been universally adopted in clinical 
practices.  The choice to use a risk assessment tool depended on how the use of it impacted 
workflow and whether the tool had credibility (Voruganti, O’Brien, Straus, McLaughlin, & 
Grunfeld, 2015).  A common theme among providers was that integrating a risk assessment tool 
into the electronic medical record would allow the tool to be easily accessible.  This would also 
serve as a reminder to providers to calculate a risk score.   Using a risk assessment tool can be 
beneficial in initiating discussion about how lifestyle choices can increase risk, especially in the 
case of smoking (Voruganti et al., 2015).  In the current practice setting, this might be a 
consideration to improve calculating the ASCVD risk score, thereby improving appropriate statin 
dosing.  
Limitations 
 One limitation of this study is that the retrospective chart review was performed at one 
primary clinic; therefore the findings cannot be generalized to a larger population.  Another 
limitation is the lack of ethnic diversity among the sample.  The third limitation is the failure of 
the electronic medical record (EMR).  Because the EMR did not date back beyond three years to 
the start of therapy for all patients, normal lipid levels, resulting from statin therapy working, 
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were calculated in the Pooled Cohort Equation as no statin indicated and therefore categorized as 
not appropriate therapy.   
According to Stone et al. (2014), 10-year ASCVD risk is to be calculated in individuals 
without clinical ASCVD every four to six years.  For this study, a risk score was calculated for 
2015 and 2016 because the EMR did not date back beyond three years.  Therefore, providers 
may have documented a risk score and determined statin treatment in prior visits unable to be 
seen.  If this differed from the principle investigators calculation of risk, the patient was 
classified as not on appropriate intensity therapy.  Lastly, 10-year ASCVD risk was calculated 
for all patients, including those with clinical ASCVD, even though ASCVD risk is only used in 
primary prevention (Stone et al., 2014).    
Implications for Practice 
 Despite the limitations of this study, knowledge has been gained.  An important 
recommendation for this clinic is to implement the ASCVD risk calculator into the EMR.  
Because research has demonstrated increases in accurate intensity statin prescribing with the use 
of a risk calculator, integrating it into the EMR will serve as a reminder to providers.  This will 
also increase the usability of the calculator into practice because it will be easily accessible.   
A person’s ASCVD risk can vary slightly depending on which values are entered by the 
provider.  Because of this, integrating it into the EMR can show exactly which values were used 
to calculate risk.  The risk score in the EMR can also serve to start a discussion between clinician 
and patient as well as allow patients to track their progress by having access to their chart.   
Making the guideline algorithm available in the medical record may also help improve 
statin prescribing in practice.  If providers were able to easily access the algorithm for statin 
prescribing in primary or secondary prevention, they may refer to it regularly to ensure accurate 
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prescribing.  Remembering to discuss healthy lifestyle habits is another important concept to take 
away from this study.  Having a hyperlipidemia care plan in the EMR may serve as a reminder to 
start a discussion.  Healthy lifestyle is the foundation of cardiovascular health and should always 
been encouraged. 
Conclusion 
Using tools from the 2013 ACC/AHA guideline in practice can help primary care 
providers educate patients, prescribe statin therapy appropriately, and decrease the risk of 
cardiovascular disease in patients with hyperlipidemia.  Using the algorithms for primary and 
secondary prevention of cardiovascular disease along with the risk calculator can improve 
accurate statin prescribing among providers.  Integrating the risk calculator and guideline 
algorithm into the EMR can increase usability and accessibility for providers along with serving 
as a reminder of the evidence-based recommendations.  It will also provide a visual when 
educating the patient about cardiovascular risk.  
Integrating the risk calculator into a specified place in the EMR will allow for better 
tracking for quality and performance measures in future quality improvement projects.  More 
accurate tracking will be beneficial when evaluating effective interventions to increase 
hyperlipidemia control.  Accurate prescribing of statin medications along with correct 
management of hyperlipidemia can help to decrease the burden associated with cardiovascular 
disease providing better quality of life for the people of Kentucky. 
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Table 1  
2013 ACC/AHA Guideline for Recommended Statin Intensity 
 
Intensity dosing of statin medication 
High-Intensity Moderate-Intensity Low-Intensity 
Daily dose lowers LDL-C on 
average, by approximately ≥ 
50% 
Daily dose lowers LDL-C on 
average, by approximately 
30% to < 50% 
Daily dose lowers LDL-C on 
average, by < 30% 
Atorvastatin 40-80 mg Atorvastatin 10-20 mg Simvastatin 10 mg 
Rosuvastatin 20-40 mg Rosuvastatin 5-10 mg Pravastatin 10-20 mg 
 Simvastatin 20-40 mg Lovastatin 20 mg 
 Pravastatin 40-80 mg Fluvastatin 20-40 mg 
 Lovastatin 40 mg Pitavastatin 1 mg 
 Fluvastatin XL 80 mg  
 Fluvastatin 40 mg BID  
 Pitavastatin 2-4 mg  
 
(Stone et al., 2014, p. 25) 
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Table 2 
Demographics and Descriptive Statistics for 2016 
 
  
2016 
N = 150 
 
2016 Appropriate Statin 
Therapy 
Age 
   40-50 
   51-60 
   61-70 
   71-75 
 
23 (15%) 
53 (35%) 
54 (36%) 
20 (13%) 
 
11 (48%) 
25 (47%) 
34 (63%) 
18 (90%)  
Gender 
   Male 
   Female 
 
74 (49%) 
76 (51%) 
 
51 (69%) 
37 (49%) 
Race 
  White 
  Other 
 
109 (73%) 
41 (27%) 
 
64 (59%) 
24 (59%) 
Hypertension 132 (88%) 75 (57%) 
Diabetes 74 (49%) 40 (54%) 
Obesity 94 (63%) 60 (64%) 
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Table 3 
Demographics and Descriptive Statistics for 2015  
 
 
 
 
2015 
N = 138 
 
2015 Appropriate Statin 
Therapy 
Age 
   40-50 
   51-60 
   61-70 
   71-75 
 
17 (12%) 
51 (37%) 
52 (38%) 
18 (13%) 
 
6 (35%) 
21 (41%) 
32 (62%) 
14 (78%) 
Gender 
   Male 
   Female 
 
68 (49%) 
70 (51%) 
 
46 (68%) 
27 (39%) 
Race 
  White 
  Other 
 
101 (73%) 
37 (27%) 
 
56 (55%) 
17 (46%) 
Hypertension 124 (90%) 64 (52%) 
Diabetes 68 (49%) 33 (49%) 
Obesity 83 (60%) 47 (57%) 
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Legend: CKD = Chronic Kidney Disease; PAD = Peripheral Arterial Disease; CVA = Cerebrovascular Accident;  
MI = Myocardial Infarction; NASH = Non-alcoholic Steatohepatitis  
 
Figure 1: Present Co-morbidities  
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Appendix A 
Chart Audit Tool 
Care Team: _______________________ 
Gender: __________________________ 
Age: _____________________________ 
Race: ____________________________ 
 
Co-morbid conditions:  
Condition Yes No 
Hypertension   
Diabetes Mellitus   
Chronic kidney disease   
Peripheral arterial disease   
Cerebrovascular Accident   
s/p Myocardial Infarction or 
stent placement 
  
Nonalcoholic steatohepatitis or 
cirrhosis 
  
Hepatitis C   
Obesity   
 
Current statin medication and dose: __________________________________ 
How long have they been on the statin: _________________________________ 
Any dose changes: __________________________________________________ 
 
Was the following documented for the patient with a diagnosis of Hyperlipidemia: 
 Yes in 2016 No in 2016 Yes in 2015 No in 2015 
Is discussion about 
healthy diet present? 
    
Discussion of 
exercise present? 
    
Discussion of 
smoking cessation 
present if applicable? 
    
Is the patient 
currently on the 
appropriate intensity 
statin therapy? 
    
If not on appropriate 
intensity, is a reason 
documented? 
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Is there a calculated 
ASCVD risk 
charted?  
    
Does it match PI’s 
calculated ASCVD 
risk? 
    
 
 Yes  No 
Were liver enzymes 
checked prior to 
initiation of statin 
therapy? 
  
Were liver enzymes 
checked yearly? 
  
Were yearly lipid 
panels completed? 
  
Is the patient 
prescribed Niacin? 
  
Is the patient 
prescribed a bile acid 
sequestrant 
(cholestyramine, 
colestipol, or 
colesevelam)? 
  
Is the patient 
prescribed 
ezetimibe? 
  
Is the patient 
prescribed a Fibrate 
(fenofibrate or 
gemfibrozil)? 
  
Is the patient taking 
omega-3 fatty acids? 
  
 
Calculated ASCVD risk for 2016:  ___________________________________ 
 
Calculated ASCVD risk for 2015: ____________________________________ 
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Appendix B 
Guideline Algorithm  
 
 
(Stone et al., 2014, p. 15) 
